CA3179965A1 - Compositions and methods useful for the prevention and/or treatment of disease in mammals - Google Patents
Compositions and methods useful for the prevention and/or treatment of disease in mammals Download PDFInfo
- Publication number
- CA3179965A1 CA3179965A1 CA3179965A CA3179965A CA3179965A1 CA 3179965 A1 CA3179965 A1 CA 3179965A1 CA 3179965 A CA3179965 A CA 3179965A CA 3179965 A CA3179965 A CA 3179965A CA 3179965 A1 CA3179965 A1 CA 3179965A1
- Authority
- CA
- Canada
- Prior art keywords
- ksp37
- protein
- viral
- subject
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001132—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Marine Sciences & Fisheries (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2020/04008 | 2020-07-09 | ||
| ZA2020/03850 | 2020-07-09 | ||
| ZA202003850 | 2020-07-09 | ||
| ZA202004008 | 2020-07-09 | ||
| PCT/IB2021/056179 WO2022009165A1 (en) | 2020-07-09 | 2021-07-09 | Compositions and methods useful for the prevention and/or treatment of disease in mammals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3179965A1 true CA3179965A1 (en) | 2022-01-13 |
Family
ID=79552952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3179965A Pending CA3179965A1 (en) | 2020-07-09 | 2021-07-09 | Compositions and methods useful for the prevention and/or treatment of disease in mammals |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240091310A1 (https=) |
| EP (1) | EP4178604A4 (https=) |
| JP (1) | JP2023533162A (https=) |
| KR (1) | KR20230038230A (https=) |
| CN (1) | CN115720520A (https=) |
| AU (1) | AU2021304479A1 (https=) |
| BR (1) | BR112022026874A2 (https=) |
| CA (1) | CA3179965A1 (https=) |
| CL (1) | CL2023000073A1 (https=) |
| CO (1) | CO2022019251A2 (https=) |
| IL (1) | IL299661A (https=) |
| MX (1) | MX2023000113A (https=) |
| PE (1) | PE20231554A1 (https=) |
| PH (1) | PH12023550038A1 (https=) |
| WO (1) | WO2022009165A1 (https=) |
| ZA (1) | ZA202213371B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025215561A1 (en) * | 2024-04-09 | 2025-10-16 | Viro-Gen (Pty) Ltd | Plasmid for expression of ksp37 |
| WO2025221871A1 (en) * | 2024-04-16 | 2025-10-23 | The Trustees Of Columbia University In The City Of New York | Expansion, propagation, and modulation of immune cell subsets by peptides |
| WO2025233868A1 (en) * | 2024-05-07 | 2025-11-13 | Viro-Gen (Pty) Ltd | Compounds, compositions and methods for treating, reversing or preventing cancer |
| WO2025233869A1 (en) * | 2024-05-07 | 2025-11-13 | Viro-Gen (Pty) Ltd | Compounds, compositions and methods for treating, reversing or preventing type 2 diabetes mellitus |
-
2021
- 2021-07-09 BR BR112022026874A patent/BR112022026874A2/pt unknown
- 2021-07-09 US US18/004,631 patent/US20240091310A1/en active Pending
- 2021-07-09 AU AU2021304479A patent/AU2021304479A1/en active Pending
- 2021-07-09 CN CN202180042656.8A patent/CN115720520A/zh active Pending
- 2021-07-09 PE PE2022003070A patent/PE20231554A1/es unknown
- 2021-07-09 MX MX2023000113A patent/MX2023000113A/es unknown
- 2021-07-09 CA CA3179965A patent/CA3179965A1/en active Pending
- 2021-07-09 WO PCT/IB2021/056179 patent/WO2022009165A1/en not_active Ceased
- 2021-07-09 PH PH1/2023/550038A patent/PH12023550038A1/en unknown
- 2021-07-09 JP JP2022575231A patent/JP2023533162A/ja active Pending
- 2021-07-09 EP EP21838245.5A patent/EP4178604A4/en active Pending
- 2021-07-09 KR KR1020237004448A patent/KR20230038230A/ko active Pending
- 2021-07-09 IL IL299661A patent/IL299661A/en unknown
-
2022
- 2022-12-09 ZA ZA2022/13371A patent/ZA202213371B/en unknown
- 2022-12-29 CO CONC2022/0019251A patent/CO2022019251A2/es unknown
-
2023
- 2023-01-06 CL CL2023000073A patent/CL2023000073A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023533162A (ja) | 2023-08-02 |
| EP4178604A4 (en) | 2024-07-31 |
| PH12023550038A1 (en) | 2024-03-11 |
| KR20230038230A (ko) | 2023-03-17 |
| WO2022009165A1 (en) | 2022-01-13 |
| IL299661A (en) | 2023-03-01 |
| BR112022026874A2 (pt) | 2023-01-24 |
| AU2021304479A1 (en) | 2023-01-19 |
| PE20231554A1 (es) | 2023-10-03 |
| MX2023000113A (es) | 2023-03-16 |
| EP4178604A1 (en) | 2023-05-17 |
| ZA202213371B (en) | 2023-11-29 |
| CO2022019251A2 (es) | 2023-03-27 |
| CN115720520A (zh) | 2023-02-28 |
| US20240091310A1 (en) | 2024-03-21 |
| CL2023000073A1 (es) | 2023-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240091310A1 (en) | Compositions and methods useful for the prevention and/or treatment of disease in mammals | |
| JP7551157B2 (ja) | Ｈｉｖワクチン接種および免疫療法 | |
| JP7162895B2 (ja) | Ｈｉｖ予備免疫化および免疫療法 | |
| JP7260170B2 (ja) | 事前の免疫化ステップのないｈｉｖ免疫療法 | |
| JP2019517503A (ja) | 遺伝子編集戦略によるｈｉｖ−１のネガティブフィードバック調節 | |
| CN110770338A (zh) | 由人γ-δ T细胞激活肿瘤细胞毒性的方法和组合物 | |
| US20240141374A1 (en) | On demand expression of exogenous factors in lymphocytes | |
| WO2019191314A1 (en) | Methods of manufacturing genetically-modified lymphocytes | |
| JPWO2022244801A5 (https=) | ||
| OA21071A (en) | Compositions and methods useful for the prevention and/or treatment of disease in mammals. | |
| EP0817859B1 (en) | Recombinant dna vectors for gene therapy | |
| WO1998003669A9 (en) | Vectors for inhibiting hiv and tumor growth | |
| WO2025064901A2 (en) | Hiv vaccination and immunotherapy | |
| EP4698202A1 (en) | Nucleic acid vaccine for activating nkg2c+ natural killer cells | |
| JP2016067306A (ja) | ヒト免疫不全ウイルスの感染防御方法 | |
| WO2025157808A1 (fr) | Production de vecteurs toxiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250704 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250704 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250709 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250709 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250709 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250714 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250911 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250911 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250911 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250911 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250911 |